In 2021, almost 10 million people in the GCC were protected by Sanofi vaccines, a source of great pride which drives us forward
In Conversation
[Advanced] therapies are complex, difficult, and have a huge public health impact, which means that the development and approval process is long and challenging
My hope is that health sector R&D funding, especially towards translational research, will continue to increase in Korea, and we will need to work harder and…
The pandemic has put [the medtech] sector in the spotlight, and we have shown that we are an innovative and committed industry
While the performance of the Spanish R&I system still lags behind the EU average in many indicators, its biotech ecosystem has been able to mature, growing…
We will continue to focus on executing our strategy as precisely as possible, working closely with patient organisations, HCPs, regulators, payers and other relevant stakeholders to…
The market share of biosimilars in Spain has been increasing but the returns on investment have decreased steadily
In retrospect, putting all our resources and efforts into becoming one of the best vaccine developers in the world has made HIPRA a great organisation
Challenges translate into opportunity for action which can in turn increase efficiency
Catalonia is special for the heterogeneity of its ecosystem. The region has excellent research centres with results that are competitive with the rest of Europe
Hopefully, with the arrival of next-generation funds [in Catalonia], there will be new initiatives that incentive investment in life sciences start-ups, such as the creation of…
As part of its transition to becoming an innovative powerhouse, Ferrer has chosen to develop drugs by acquiring products in early stages, usually phase I or…
